We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Limiting Secondary Damage of Brain Injury

By HospiMedica staff writers
Posted on 20 May 2002
A new study will seek to determine whether cyclosporin A, a chemotherapy drug, can limit some of the secondary damage, such as swelling, that occurs in patients with severe traumatic brain injury.

Researchers at the University of Florida (Gainesville, FL, US) theorize that head injury damages nerve cells in the brain, which renders them less able to regulate the flow of chemicals, especially calcium, in and out of the cells. More...
A buildup of calcium inside the cell causes progressive damage to the mitochondria and finally kills the nerve cells. By treating the victims of severe brain injury within 12 hours with cyclosporin A, the researchers hope to prevent this delayed response that causes cell death. They say the new treatment may also be effective for stroke, hemorrhage, and tumors.

In animal studies, a low dose of the drug was shown to regulate the flow of calcium into cells, thereby preventing injury to mitochrondia. The drug will be administered through an intravenous catheter to patients who arrive at the hospital within eight hours of the injury. Brain levels will be evaluated through a catheter inserted parallel to the tube routinely used to measure pressure inside the brain. The catheter will also be used to sample substances from the brain to determine whether they contain breakdown products indicative of nerve cell death.

"We're trying to separate the events associated with head injury that are primary—meaning they're a product of the injury itself—from the reactions or misdirected healing attempts by the body that end up being more destructive than the actual injury,” said A. Joseph Layon, M.D., professor of critical care medicine in the department of anesthesiology, who is directing the study.




Related Links:
Univ. of Florida

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.